Aditxt Announces Closing of $20.0 Million Public Offering
September 20 2022 - 4:09PM
Business Wire
Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a
biotech innovation company developing and commercializing
technologies focused on monitoring and modulating the immune
system, today announced the closing of its previously announced
public offering of 3,333,333 shares of its common stock (or common
stock equivalents in lieu thereof), together with warrants to
purchase up to 3,333,333 shares of its common stock at a combined
offering price to the public of $6.00 per share (or common stock
equivalent) and associated warrant. The warrants have an exercise
price of $6.00 per share, are exercisable immediately upon
issuance, and will expire five years following the date of
issuance.
H.C. Wainwright & Co. acted as the exclusive placement agent
for the offering.
The gross proceeds to the Company from the offering were
approximately $20.0 million, before deducting the placement agent’s
fees and other offering expenses payable by the Company. The
Company intends to use the net proceeds from this offering for
continued operating expenses and working capital.
The securities described above were offered pursuant to a
registration statement on Form S-1 (File No. 333-266183) initially
filed with the Securities and Exchange Commission (SEC) on July 18,
2022 and became effective on September 16, 2022. The public
offering was made only by means of a prospectus, which forms a part
of the effective registration statement. Electronic copies of the
final prospectus may be obtained for free on the SEC’s website
located at http://www.sec.gov and may also be obtained by
contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd
Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at
placements@hcwco.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or other jurisdiction in which such an offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About Aditxt
Aditxt is a biotech innovation company developing and
commercializing technologies focused on monitoring and modulating
the immune system. Aditxt’s immune monitoring technologies are
designed to provide a personalized immune profile. Aditxt’s immune
modulating technologies, currently preclinical, are being developed
to retrain the immune system to induce tolerance to address
rejection of transplanted organs, autoimmune diseases and
allergies. For more information, please visit www.Aditxt.com and
www.AditxtScore.com
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company's intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company's ongoing and planned product and business development;
the Company's intellectual property position; the Company's ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company's results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as market and other conditions and those risks
more fully discussed in the section titled "Risk Factors" in the
Company's most recent Annual Report on Form 10-K, as well as
discussions of potential risks, uncertainties, and other important
factors in the Company's other filings with the Securities and
Exchange Commission. All such statements speak only as of the date
made, and the Company undertakes no obligation to update or revise
publicly any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220920006224/en/
Media and Investor Relations Contact: ir@aditxt.com
www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Apr 2023 to Apr 2024